Clinical trial • Phase III • Oncology
LY4170156 for Fallopian tube cancer | Peritoneal cancer | Ovarian cancer | Metastatic cancer
Phase III trial of LY4170156 for Fallopian tube cancer | Peritoneal cancer | Ovarian cancer | Metastatic cancer.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Fallopian tube cancer | Peritoneal cancer | Ovarian cancer | Metastatic cancer
- Trial Stage
- Phase III
- Drug Modality
- ADC|Monoclonal antibody|Small molecule
Key dates
- Initial CTIS Submission Date
- 21-01-2026
- First CTIS Authorization Date
- 11-05-2026
Trial design
Part A control: investigator’s choice of chemotherapy or Mirvetuximab Soravtansine (MIRV). Part B control: investigator’s choice of platinum-based doublet chemotherapy plus bevacizumab. (Comparator agents listed in CTIS product list include carboplatin, paclitaxel, pegylated liposomal doxorubicin (doxorubicin), topotecan, gemcitabine, and mirvetuximab soravtansine; bevacizumab is used in combination in Part B.) Phase III trial in Hungary, Ireland, Italy and others.
- Comparator
- Part A control: investigator’s choice of chemotherapy or Mirvetuximab Soravtansine (MIRV). Part B control: investigator’s choice of platinum-based doublet chemotherapy plus bevacizumab. (Comparator agents listed in CTIS product list include carboplatin, paclitaxel, pegylated liposomal doxorubicin (doxorubicin), topotecan, gemcitabine, and mirvetuximab soravtansine; bevacizumab is used in combination in Part B.)
- Target Sample Size
- 639
Eligibility
Recruits 639 No vulnerable population selected (isVulnerablePopulationSelected is false in CTIS). No specific vulnerable-population consent/assent handling is provided in the CTIS record..
- Vulnerable Population
- No vulnerable population selected (isVulnerablePopulationSelected is false in CTIS). No specific vulnerable-population consent/assent handling is provided in the CTIS record.
Inclusion criteria
- {"criterion_text":"- Have ovarian, peritoneal, or fallopian tube cancer."}
- {"criterion_text":"- Have adequate organ function and blood counts, as measured by blood tests"}
- {"criterion_text":"- Be well enough to walk and do light work"}
- {"criterion_text":"- (Part A): Have had their cancer return or worsen 6 months or less after their last platinum chemotherapy."}
- {"criterion_text":"- (Part B): Have had their cancer return or worsen 6 months or more after the last platinum chemotherapy."}
Exclusion criteria
- {"criterion_text":"- Have taken a special kind of medicine called an \"antibody-drug conjugate\" that has a topoisomerase inhibitor (DNA untangler) in it."}
- {"criterion_text":"- (Part A): Have had their cancer return or worsen within the first 3 months after the last dose of the first treatment with platinum chemotherapy."}
- {"criterion_text":"- (Part B): Have too much protein in the urine (called \"proteinuria\")."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Part A: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator\n- Part B: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded, independent, central review (BICR)","definition_or_measurement_approach":"Part A measured as PFS per RECIST v1.1 assessed by Investigator; Part B measured as PFS per RECIST v1.1 by blinded independent central review (BICR)."}
Recruitment
- Digital Remote Recruitment
- True, recruitment and participant engagement materials include digital/remote elements and eSource/eCOA platforms (vendors listed in third parties include Medable Inc. for eSource/eCOA, and documents reference Study Connect participant materials and video storyboard/online retention materials).
- Planned Sample Size
- 639
- Recruitment Window Months
- 65
- Consent Approach
- Informed consent is via subject information sheets and informed consent forms (main and prescreening versions) and optional consent addenda (e.g., optional biopsy, genetic research) provided per country. Country/language-specific ICFs are present in the document list (examples: English, Greek, Hungarian, Dutch, Italian, Polish, French, Norwegian, Czech, Romanian, and others as per country-specific ICF documents).
Methods
- Country-specific recruitment materials and channels documented: flyers, posters, brochures (K2_Recruitment material files) for multiple countries (examples in document list for Ireland, Hungary, Netherlands, Poland, Belgium, Germany, Norway, Italy, Czechia, France).
- Doctor referral letters / physician referral (K2 'Letter-Doctor-Referral' documents) to engage clinicians for patient identification.
- Site-based recruitment and patient contact cards / visit cards / study guides (L2 and L1 documents listed per country) distributed at participating hospitals/clinics.
- Retention and participant engagement materials including a CT video storyboard and postcard (document titles: CT Video-Storyboard, CT_Postcard) and digital participant connection materials (Study Connect).
Geography
- Total Number Of Sites
- 62
- Total Number Of Participants
- 387
Hungary
- Earliest CTIS Part Ii Submission Date
- 13-03-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 63
- Number Of Sites
- 2
- Number Of Participants
- 7
Sites
- Site Name
- Orszagos Onkologiai Intezet
- Department Name
- Nogyogyaszat
- Contact Person Name
- Andrea Bagameri
- Contact Person Email
- bagameristudy@gmail.com
- Site Name
- University Of Debrecen
- Department Name
- Szuleszeti es Nogyogyaszati Klinika
- Contact Person Name
- Robert Poka
- Contact Person Email
- pokar@med.unideb.hu
Ireland
- Earliest CTIS Part Ii Submission Date
- 13-04-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 32
- Number Of Sites
- 3
- Number Of Participants
- 13
Sites
- Site Name
- St Vincent's University Hospital
- Department Name
- Medical Oncology
- Contact Person Name
- Lynda McSorley
- Contact Person Email
- yndamcsorley@svhg.ie
- Site Name
- St James's Hospital
- Department Name
- Haematology Oncology Palliative Care (HOPe)
- Contact Person Name
- Karen Cadoo
- Contact Person Email
- KCadoo@stjames.ie
- Site Name
- Cork University Hospital
- Department Name
- Medical Oncology
- Contact Person Name
- Dearbhaile Collins
- Contact Person Email
- dearbhaile.collins@hse.ie
Italy
- Earliest CTIS Part Ii Submission Date
- 16-03-2026
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 57
- Number Of Sites
- 12
- Number Of Participants
- 49
Sites
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- SSD Oncologia Medica Zamagni
- Contact Person Name
- Claudio Zamagni
- Contact Person Email
- zamagniclaudio.sper@aosp.bo.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Ginecologia Oncologica
- Contact Person Name
- Anna Fagotti
- Contact Person Email
- anna.fagotti@policlinicogemelli.it
- Site Name
- Azienda Ospedaliera Per L'Emergenza Cannizzaro
- Department Name
- Oncologia medica
- Contact Person Name
- Giuseppe Scandurra
- Contact Person Email
- giusy.scandurra@gmail.com
- Site Name
- Istituto Europeo Di Oncologia S.r.l.
- Department Name
- Divisione Ginecologia Oncologica
- Contact Person Name
- Nicoletta Colombo
- Contact Person Email
- nicoletta.colombo@ieo.it
- Site Name
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Department Name
- Oncologia medica
- Contact Person Name
- Monika Ducceschi
- Contact Person Email
- monika.ducceschi@istitutotumori.mi.it
- Site Name
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Department Name
- S.C. Oncologia Sperimentale Uro-Genitale
- Contact Person Name
- Sabrina Cecere
- Contact Person Email
- s.cecere@istitutotumori.na.it
- Site Name
- Azienda Unita Sanitaria Locale Della Romagna
- Department Name
- Oncologia medica
- Contact Person Name
- Claudia Casanova
- Contact Person Email
- casanova.claudia@libero.it
- Site Name
- Ospedale Vito Fazzi Lecce
- Department Name
- Medical Oncology University
- Contact Person Name
- Ugo De Giorgi
- Contact Person Email
- ugo.degiorgi@unisalento.it
- Site Name
- Azienda USL Toscana Centro
- Department Name
- SOC Oncologia Medica
- Contact Person Name
- Elena Zafarana
- Contact Person Email
- elena.zafarana@uslcentro.toscana.it
- Site Name
- Azienda Ospedaliero Universitaria Di Modena
- Department Name
- DH Oncologia
- Contact Person Name
- Cinzia Baldessari
- Contact Person Email
- baldessari.cinzia@aou.mo.it
- Site Name
- Azienda Unita' Sanitaria Locale Toscana Nord Ovest
- Department Name
- Oncology
- Contact Person Name
- Editta Baldini
- Contact Person Email
- editta.baldini@uslnordovest.toscana.it
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- U.O. Ginecologia Oncologica Medica
- Contact Person Name
- Domenica Lorusso
- Contact Person Email
- domenica.lorusso@hunimed.eu
Netherlands
- Earliest CTIS Part Ii Submission Date
- 06-05-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 5
- Number Of Sites
- 2
- Number Of Participants
- 21
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Medical Oncology
- Contact Person Name
- Ingrid Boere
- Contact Person Email
- i.boere@erasmusmc.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Medical Oncology
- Contact Person Name
- An Reyners
- Contact Person Email
- a.k.l.reyners@umcg.nl
Norway
- Earliest CTIS Part Ii Submission Date
- 06-05-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 5
- Number Of Sites
- 2
- Number Of Participants
- 7
Sites
- Site Name
- Oslo Universitetssykehus HF
- Department Name
- Gynaecological Oncology
- Contact Person Name
- Kristina Lindemann
- Contact Person Email
- klinde@ous-hf.no
- Site Name
- Helse Stavanger HF
- Department Name
- Gynecology and Obstetrics
- Contact Person Name
- Elisabeth Berge Nilsen
- Contact Person Email
- elisabeth.berge.nilsen@sus.no
Poland
- Earliest CTIS Part Ii Submission Date
- 10-04-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 35
- Number Of Sites
- 5
- Number Of Participants
- 56
Sites
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Department Name
- Kinika Ginekologii Onkologicznej I Endokrynologii Ginekologicznej
- Contact Person Name
- Dagmara Klasa-Mazurkiewicz
- Contact Person Email
- dklasa@gumed.edu.pl
- Site Name
- Wielkopolskie Centrum Onkologii Im. Marii Sklodowskiej-Curie
- Department Name
- Oddział Radioterapii i Onkologii Ginekologicznej
- Contact Person Name
- Bartosz Urbański
- Contact Person Email
- bartosz.urbanski@wco.pl
- Site Name
- Mazowiecki Szpital Wojewodzki w Siedlcach Sp. z o.o.
- Department Name
- Siedleckie Centrum Onkologii
- Contact Person Name
- Lubomir Bodnar
- Contact Person Email
- lbodnar@szpital.siedlce.pl
- Site Name
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
- Department Name
- Poradnia Onkologiczna oraz Oddział Kliniczny Onkologii
- Contact Person Name
- Piotr Wysocki
- Contact Person Email
- piotr.wysocki@uj.edu.pl
- Site Name
- Uniwersytecki Szpital Kliniczny W Bialymstoku
- Department Name
- Uniwersyteckie Centrum Onkologii
- Contact Person Name
- Paweł Knapp
- Contact Person Email
- knapp@umb.edu.pl
Belgium
- Earliest CTIS Part Ii Submission Date
- 15-04-2026
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 27
- Number Of Sites
- 5
- Number Of Participants
- 28
Sites
- Site Name
- Universitair Ziekenhuis Antwerpen
- Department Name
- Oncology
- Contact Person Name
- Laure-Anne Teuwen
- Contact Person Email
- laure-anne.teuwen@uza.be
- Site Name
- Az Maria Middelares Gent
- Department Name
- IKG
- Contact Person Name
- Christof Vulsteke
- Contact Person Email
- christof.vulsteke@mijnziekenhuis.be
- Site Name
- AZ ST-JAN Brugge A.V.
- Department Name
- Oncology and /or Hematology
- Contact Person Name
- Eveline De Cuypere
- Contact Person Email
- eveline.decuypere@azsintjan.be
- Site Name
- UZ Leuven
- Department Name
- Gynecologic Oncology
- Contact Person Name
- Els Van Nieuwenhuysen
- Contact Person Email
- els.vannieuwenhuysen@uzleuven.be
- Site Name
- Institut Jules Bordet
- Department Name
- Clinical Trial Conduct Unit (Completed) / Medicine Oncology (Incomplete)
- Contact Person Name
- Laura Polastro
- Contact Person Email
- laura.polastro@hubruxelles.be
Czechia
- Earliest CTIS Part Ii Submission Date
- 29-04-2026
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 13
- Number Of Sites
- 5
- Number Of Participants
- 49
Sites
- Site Name
- Fakultni Nemocnice Brno
- Department Name
- Gynekologicko-porodnická klinika
- Contact Person Name
- Markéta Bednaříková
- Contact Person Email
- Bednarikova.Marketa@fnbrno.cz
- Site Name
- Nemocnice AGEL Novy Jicin a.s.
- Department Name
- Oddělení radioterapie a onkologie
- Contact Person Name
- Vojtěch Tlustý
- Contact Person Email
- vojtech.tlusty@nnj.agel.cz
- Site Name
- Krajska Nemocnice T Bati a.s.
- Department Name
- Onkologické oddělení
- Contact Person Name
- Markéta Pospíšková
- Contact Person Email
- pospiskova@bnzlin.cz
- Site Name
- University Hospital Olomouc
- Department Name
- Onkologická klinika
- Contact Person Name
- Bohuslav Melichar
- Contact Person Email
- bohuslav.melichar@fnol.cz
- Site Name
- Všeobecná fakultní nemocnice v Praze
- Department Name
- Gynekologicko porodnická klinika
- Contact Person Name
- David Cibula
- Contact Person Email
- dc@davidcibula.cz
Denmark
- Earliest CTIS Part Ii Submission Date
- 30-04-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 11
- Number Of Sites
- 2
- Number Of Participants
- 21
Sites
- Site Name
- Lillebaelt Hospital
- Department Name
- Oncology
- Contact Person Name
- Caroline Brenner Thomsen
- Contact Person Email
- caroline.emilie.brenner.thomsen@rsyd.dk
- Site Name
- Rigshospitalet
- Department Name
- Oncology
- Contact Person Name
- Trine Jakobi Nøttrup
- Contact Person Email
- trine.jakobi.noettrup@regionh.dk
France
- Earliest CTIS Part Ii Submission Date
- 09-04-2026
- Latest Decision Or Authorization Date
- 13-05-2026
- Processing Time Days
- 34
- Number Of Sites
- 11
- Number Of Participants
- 77
Sites
- Site Name
- Les Hopitaux Universitaires De Strasbourg
- Department Name
- Oncology and Hematology
- Contact Person Name
- Lauriane EBERST
- Contact Person Email
- l.eberst@icans.eu
- Site Name
- Centre Hospitalier de la Côte Basque
- Department Name
- Oncology
- Contact Person Name
- Thomas GRELLETY
- Contact Person Email
- tgrellety@ch-cotebasque.fr
- Site Name
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
- Department Name
- Oncology
- Contact Person Name
- Coriolan LEBRETON
- Contact Person Email
- c.lebreton@bordeaux.unicancer.fr
- Site Name
- Centre Oscar Lambret
- Department Name
- Oncology
- Contact Person Name
- Mathilde SAINT-GHISLAIN
- Contact Person Email
- m-saintghislain@o-lambret.fr
- Site Name
- Institut de Cancérologie de l'Ouest
- Department Name
- Oncology
- Contact Person Name
- Paule AUGEREAU
- Contact Person Email
- paule.augereau@ico.unicancer.fr
- Site Name
- Institut Regional Du Cancer De Montpellier
- Department Name
- Oncology
- Contact Person Name
- Stanislas QUESADA
- Contact Person Email
- stanislas.quesada@icm.unicancer.fr
- Site Name
- Hôpitaux Universitaires Paris Centre-Hôpital Cochin
- Department Name
- Service d'Oncologie Medicale
- Contact Person Name
- Jerôme ALEXANDRE
- Contact Person Email
- jerome.alexandre@aphp.fr
- Site Name
- Groupe Hospitalier Diaconesses Croix Saint Simon
- Department Name
- URCEC
- Contact Person Name
- Antoine ANGELERGUES
- Contact Person Email
- aangelergues@hopital-dcss.org
- Site Name
- Centre Léon Bérard
- Department Name
- Oncology
- Contact Person Name
- Isabelle-Laure RAY-COQUARD
- Contact Person Email
- isabelle.ray-coquard@lyon.unicancer.fr
- Site Name
- Centre Hospitalier Et Universitaire De Limoges
- Department Name
- Oncologie
- Contact Person Name
- Elise DELUCHE
- Contact Person Email
- elise.deluche@chu-limoges.fr
- Site Name
- CHRU de Brest
- Department Name
- Institut de cancérologie et d'Hématologie
- Contact Person Name
- Laura DEIANA
- Contact Person Email
- laura.deiana@chu-brest.fr
Germany
- Earliest CTIS Part Ii Submission Date
- 30-04-2026
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 12
- Number Of Sites
- 9
- Number Of Participants
- 39
Sites
- Site Name
- Technische Universitaet Dresden
- Department Name
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Contact Person Name
- Pauline Wimberger
- Contact Person Email
- pauline.wimberger@uniklinikum-dresden.de
- Site Name
- Universitaetsklinikum Aachen AöR
- Department Name
- Frauenklinik
- Contact Person Name
- Elmar Stickeler
- Contact Person Email
- estickeler@ukaachen.de
- Site Name
- Charité Campus Virchow-Klinikum
- Department Name
- Charité Campus Virchow-Klinikum
- Contact Person Name
- Elena Braicu
- Contact Person Email
- elena.braicu@charite.de
- Site Name
- Universitaetsklinikum Koeln AöR
- Department Name
- Klinik und Poliklinik für Frauenheilkunde und Gynäkologische Onkologie
- Contact Person Name
- Florin Andrei Taran
- Contact Person Email
- florin-andrei.taran@uk-koeln.de
- Site Name
- Universitaetsklinikum Erlangen AöR
- Department Name
- Klinik für Gynäkologie und Geburtshilfe
- Contact Person Name
- Peter Fasching
- Contact Person Email
- peter.fasching.studien@uk-erlangen.de
- Site Name
- KEM I Evang. Kliniken Essen-Mitte gGmbH
- Department Name
- Klinik für Gynäkologie und Gynäkologische Onkologie
- Contact Person Name
- Sabrina Kaiser
- Contact Person Email
- sa.kaiser@kem-med.com
- Site Name
- Universitaetsklinikum Bonn AöR
- Department Name
- Gynaecological oncology
- Contact Person Name
- Eva-Katharina Egger
- Contact Person Email
- eva-katharina.egger@ukbonn.de
- Site Name
- Universitaetsklinikum Duesseldorf AöR
- Department Name
- Klinik für Frauenheilkunde & Geburtshilfe
- Contact Person Name
- Tanja Fehm
- Contact Person Email
- studien.fehm@med.uni-duesseldorf.de
- Site Name
- Universitaetsklinikum Schleswig-Holstein Campus Kiel
- Department Name
- Klinik für Gynäkologie und Geburtshilfe, Studienzentrale
- Contact Person Name
- Marion Tina van Mackelenbergh
- Contact Person Email
- marion.vanmackelenbergh@uksh.de
Greece
- Earliest CTIS Part Ii Submission Date
- 24-02-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 76
- Number Of Sites
- 4
- Number Of Participants
- 20
Sites
- Site Name
- General Oncological Hospital Of Kifissia Agioi Anargyroi
- Department Name
- Department of Medical Oncology
- Contact Person Name
- Roubini Zakopoulou
- Contact Person Email
- rzakopoul@gmail.com
- Site Name
- General Hospital Of Athens Alexandra
- Department Name
- Oncology Department, University Clinic of Therapeutics
- Contact Person Name
- Michalis Liontos
- Contact Person Email
- mliontos@gmail.com
- Site Name
- General Hospital Of Messinia
- Department Name
- Oncology Department
- Contact Person Name
- Sofia Stamatopoulou
- Contact Person Email
- stamatopouloudoubali@yahoo.gr
- Site Name
- Areteio Hospital
- Department Name
- Oncology Unit, 2nd Surgical Department
- Contact Person Name
- Flora Zagouri
- Contact Person Email
- florazagour@yahoo.co.uk
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Icon Clinical Research LLC
- Responsibilities
- Laboratory & Diagnostics:Imaging
- Name
- IQVIA Limited
- Responsibilities
- Study Development/Conduct: Site Monitoring
- Name
- PPD Global Central Labs
- Responsibilities
- Laboratory & Diagnostics: Central Lab Regional
- Name
- Kcas LLC
- Responsibilities
- Laboratory & Diagnostics: Bioanalytical Sample Analysis
- Name
- Pharmaceutical Product Development LLC
- Responsibilities
- Laboratory & Diagnostics: Central Lab & Project Management
- Name
- Medable Inc.
- Responsibilities
- Data Management: eSource, Ecoa
Third parties
- {"country":"United States","full_name":"Icon Clinical Research LLC","duties_or_roles":"Laboratory & Diagnostics:Imaging","organisation_type":"Pharmaceutical company"}
- {"country":"Greece","full_name":"Pharmaserve Lilly S.A.C.I.","duties_or_roles":"Codes: 1, 12, 15 (includes 'Negotiation and Execution of Clinical Trial Agreements with the participating sites, make study payments based on invoices'), 2, 5","organisation_type":"Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"IQVIA Limited","duties_or_roles":"Study Development/Conduct: Site Monitoring","organisation_type":"Pharmaceutical company"}
- {"country":"Belgium","full_name":"PPD Global Central Labs","duties_or_roles":"Laboratory & Diagnostics: Central Lab Regional","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Kcas LLC","duties_or_roles":"Laboratory & Diagnostics: Bioanalytical Sample Analysis","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Cleveland Clinic Foundation","duties_or_roles":"Study Development/Conduct : Adjudication","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"United States","full_name":"RWS Life Sciences Inc.","duties_or_roles":"Copyright Licensing and Translations of Scales / Questionnaires / Diaries","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Veeva Systems Inc.","duties_or_roles":"Data Management/eDC Data Management / Data Validation/ Data Review/Queries Data Management / Data Reporting / Analytics","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Pharmaceutical Product Development LLC","duties_or_roles":"Laboratory & Diagnostics: Central Lab & Project Management","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Medable Inc.","duties_or_roles":"Data Management: eSource, Ecoa","organisation_type":"Non-Pharmaceutical company"}
Investigational products
- Investigational Product Name
- LY4170156
- Active Substance
- LY4170156
- Modality
- ADC
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation (marketingAuthNumber is '-')
- Investigational Product Name
- MIRVETUXIMAB SORAVTANSINE
- Active Substance
- Mirvetuximab soravtansine
- Modality
- ADC
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation (marketingAuthNumber is '-')
- Maximum Dose
- 6 mg/kg
- Investigational Product Name
- BEVACIZUMAB
- Active Substance
- Bevacizumab
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation recorded in product entry (marketingAuthNumber is '-')
- Maximum Dose
- 15 mg/kg
- Investigational Product Name
- PACLITAXEL
- Active Substance
- Paclitaxel
- Modality
- Small molecule
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation recorded in product entry (marketingAuthNumber is '-')
- Maximum Dose
- 175 mg/m2
- Investigational Product Name
- CARBOPLATIN
- Active Substance
- Carboplatin
- Modality
- Small molecule
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation recorded in product entry (marketingAuthNumber is '-')
- Maximum Dose
- 900 mg/m2
- Investigational Product Name
- GEMCITABINE
- Active Substance
- Gemcitabine hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation recorded in product entry (marketingAuthNumber is '-')
- Maximum Dose
- 1000 mg/m2
- Investigational Product Name
- DOXORUBICIN HYDROCHLORIDE
- Active Substance
- Doxorubicin hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation recorded in product entry (marketingAuthNumber is '-')
- Maximum Dose
- 40 mg/m2
- Investigational Product Name
- TOPOTECAN
- Active Substance
- Topotecan
- Modality
- Small molecule
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- No marketing authorisation recorded in product entry (marketingAuthNumber is '-')
- Maximum Dose
- 4 mg/m2
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)